RxDoctor Payments Data

Keith Lackey, MD

Internal Medicine · Charleston, SCNPI 1154389815

Payments from drug & device makers

$6,369in general payments, 2019–2025

Across 348 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$567
  • Amgen$499
  • AbbVie$444
  • Pfizer$385
  • Novo Nordisk$381
  • GSK$339
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$6,28999%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,369 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$389,490
Medicare patients
757
Services billed
5,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$150,435
OzempicSemaglutide98$110,337
JardianceEmpagliflozin85$94,997
JanuviaSitagliptin Phosphate68$79,021
FarxigaDapagliflozin Propanediol71$76,885
MounjaroTirzepatide52$61,289
EntrestoSacubitril/Valsartan35$33,697
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$31,017
OxycontinOxycodone Hcl32$25,080
TrulicityDulaglutide14$18,931
XareltoRivaroxaban22$17,312
MyrbetriqMirabegron14$14,840
Fondaparinux Sodium15$12,116
VascepaIcosapent Ethyl13$10,898
CreonLipase/Protease/Amylase12$9,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$385$150,435161 claims
Novo NordiskOzempic$381$110,33798 claims
Boehringer IngelheimJardiance, Tradjenta$144$101,33797 claims
Lilly USA, LLCMounjaro, Trulicity$567$80,22166 claims
MerckJanuvia$110$79,02168 claims
AstraZenecaFarxiga$316$76,88571 claims
NovartisEntresto$111$33,69735 claims
GSKTrelegy Ellipta$339$31,01729 claims
AbbVieCreon, Synthroid, Restasis$444$23,067101 claims
Johnson & JohnsonXarelto$95$17,31222 claims
Astellas Pharma US IncMyrbetriq$203$14,84014 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$267$6,41411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →